Cosentyx (secukinumab) is a medication used to treat various inflammatory diseases, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug called a monoclonal antibody, which works by targeting and blocking a specific protein in the body (interleukin-17A) that contributes to inflammation [1].
Regarding the effect of Cosentyx on vaccine effectiveness, there is limited information available specifically about this drug. However, according to general knowledge about biologic medications, they may affect the immune system's response to vaccines [2]. Biologics, like Cosentyx, can suppress the immune system, which might lead to a reduced response to vaccines [2].
A study published in the Journal of Investigative Dermatology found that patients with psoriasis treated with biologic therapies, including secukinumab (Cosentyx), had a reduced response to the pneumococcal vaccine compared to those not receiving biologic therapy [3]. This suggests that patients taking Cosentyx might have a reduced response to vaccines, but more research is needed to confirm these findings and to understand the full implications for various types of vaccines.
In summary, Cosentyx may affect vaccine effectiveness due to its immunosuppressive properties. However, more research is required to determine the extent of this effect on different types of vaccines. Patients taking Cosentyx should consult their healthcare provider for specific guidance on vaccinations [2].
Sources:
1. Cosentyx (secukinumab) [Internet]. Drugs.com. [cited 2023 Feb 22]. Available from: <https://www.drugs.com/cosentyx.html>.
2. Biologic therapies and vaccines: What you need to know [Internet]. American College of Rheumatology. 2021 [cited 2023 Feb 22]. Available from: <https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/Biologics/Biologics-and-Vaccines>.
3. Armstrong AW, Wu JJ, Wu J, Lebwohl MG, Baddley JW, Hu J, et al. Impaired Vaccine Response in Patients with Psoriasis Treated with Biologic Therapies. Journal of Investigative Dermatology. 2016 Jan;136(1):152-7.e2. doi: 10.1016/j.jid.2015.09.013. Epub 2015 Oct 2. PMID: 26427533.
4. DrugPatentWatch - Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com. [cited 2023 Feb 22]. Available from: <https://www.drugpatentwatch.com/drugs/cosentyx>.